US-REGISTERED COMPANY 
EU WAREHOUSE
Bremelanotide, also known as PT-141, is a cyclic peptide associated with the melanocortin receptor system. It is studied in the context of central melanocortin signaling and functional receptor selectivity.
Melanocortin receptors
The melanocortin family contains several G-protein-coupled receptors with different tissue distributions and signaling profiles. The broad term “melanocortin agonist” therefore does not fully describe a molecule's functional profile.
What is studied in vitro?
- affinity and functional activity at individual receptors
- cellular cAMP response
- concentration-response relationships
- selectivity across receptor subtypes
- stability of the cyclic peptide structure
PT-141 and bremelanotide
PT-141 is a development identifier widely used in scientific and online sources, while bremelanotide is the generic molecular name. Scientific interpretation should distinguish the molecule, a regulated pharmaceutical product and a laboratory research material.
Related laboratory material
See the neutrally labeled PT Compound 10 mg laboratory material.
Source
FDA regulatory documentation for bremelanotide
RESEARCH USE ONLY: This educational content concerns laboratory and scientific research. Peptiva research materials are not medicines and are not intended for use in humans or animals.
Related catalogue and documentation
Common question
Is PT-141 the same as a finished bremelanotide medicine?
PT-141 is a designation associated with the bremelanotide molecule. It does not itself define a product's formulation, approval, composition or manufacturing standard. Research material should therefore not be equated with an approved medicine.